ClinicalTrials.gg
CompletedNCT02388737Updated Feb 21, 2020Results posted

Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis

A Phase 3 interventional study of Vonoprazan and Lansoprazole in Erosive Esophagitis, sponsored by Takeda. Completed at 72 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-21.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
703
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing vonoprazan in Esophagitis — 1 open to participants now, 1 under way, none of them phase 3. vonoprazan · Esophagitis.

Enrollment
2nd of 10
703 · median 357
Started
2015
with 1 other
Phase 3
7 of 10
none open now
Registered
5th of 10
by date
Lead sponsor
7 of 10
Takeda

Among the 10 studies testing vonoprazan in Esophagitis, this one is the 2nd largest by enrollment, is one of 2 that started in 2015, is one of 7 in phase 3, and was the 5th registered.

Esophagitis

123 studies on the registry are indexed under Esophagitis; 15 are open to participants now.

Browse Esophagitis studies →

Open to participants now

1 of the 10 studies testing vonoprazan in Esophagitis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vonoprazan

vonoprazan: first FDA approval 2022 (VOQUEZNA TRIPLE PAK). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 10 Esophagitis studies recruiting now, 6 (60%) set no upper age limit and 4 (40%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing vonoprazan in Esophagitis, or all of them as a file.
02

Study summary

This is a comparative study of vonoprazan (TAK-438) (10 mg or 20 mg) in participants in whom endoscopic healing of erosive esophagitis has been confirmed with vonoprazan or adequate treatment with a proton pump inhibitor (PPI), to demonstrate the non-inferiority of vonoprazan to lansoprazole in their maintenance treatment (6 months or 24 weeks) as well as to determine the clinically recommended dose for vonoprazan for maintenance therapy in erosive esophagitis.

Read the detailed description

The drug being tested in this study is called vonoprazan. Vonoprazan is being tested as a maintenance treatment for people with healed erosive esophagitis (EE). This study will look at participants in whom endoscopic healing of erosive esophagitis has been confirmed with vonoprazan or adequate treatment with a proton pump inhibitor (PPI), to demonstrate the non-inferiority of vonoprazan to Lansoprazole in their maintenance treatment (6 months or 24 weeks) as well as to determine the clinically recommended dose for vonoprazan for maintenance therapy in erosive esophagitis.

The study will enroll approximately 693 patients. Participants will be randomly assigned (by chance, like flipping a coin) to one of the three treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need):

  • TAK-438 10 mg
  • TAK-438 20 mg
  • Lansoprazole 15 mg

Participants with ongoing erosive esophagitis (EE) will receive lansoprazole 30 mg once daily for 4 or 8 weeks (the Healing phase) until healing of EE is confirmed by endoscopy performed at either Week -4 and/or Day 1 before eligible for randomization to maintenance phase. In Maintenance phase, participants with confirming EE healing will be asked to take 2 tablets and a capsule at the same time each morning after breakfast throughout the study. All participants will be asked to record daytime and nighttime (during sleep) subjective symptoms in a diary on a daily basis.

This multi-centre trial will be conducted worldwide. The overall time to participate in this study is 8 months. Participants will make multiple visits to the clinic, and will be contacted by telephone 7-14 days after last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Erosive Esophagitis

Browse trials for

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedures.
  3. Has been confirmed on endoscopy to have had erosive esophagitis [Los Angeles (LA) classification grades A to D] within 84 days of Day 1.
  4. If the participant is not rolled over from TAK-438_303 study, he/she has undergone an open-label Proton pump inhibitor (PPI) treatment (Lansoprazole 30 mg, once daily) of 4 or 8 weeks within the TAK-438_305 protocol.
  5. Has been confirmed on endoscopy to have healing of erosive esophagitis. This endoscopy, if not part of the TAK-438_303 study, must have been within the last 14 days prior to randomization, otherwise the endoscopy must be repeated to confirm healing before randomization in the TAK-438_305 study.
  6. Is aged 18 years old or older (or the local age of consent if that is older), male or female, at the time of signing an informed consent, and is being treated on an outpatient basis for erosive esophagitis, including those temporarily admitted for examination.
  7. A female participant of who is sexually active with a nonsterilized male partner agrees to use routinely adequate from signing of informed consent throughout the duration of the study and for 4 weeks after last dose of study medication.

Exclusion criteria

Exclusion Criteria:

  1. Has received any compound (other than study TAK-438_303) within 84 days prior to screening phase.
  2. Has received TAK-438 in a previous clinical study (other than study TAK-438_303) or as a therapeutic agent.
  3. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
  4. Has, in the judgment of the investigator, abnormal hematological parameters of , hematocrit, or erythrocytes at Screening.
  5. Has a history or clinical manifestations of significant central nervous system (CNS), cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urological, endocrine or hematological disease.
  6. Has a history of or allergies to TAK-438 or to proton pump inhibitors (PPIs) including any associated .
  7. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 1 year prior to the start the screening phase.
  8. Is required to take excluded medications.
  9. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period.
  10. Has participated in another clinical study (other than study TAK-438_303) within the past 30 days from Visit 1.
  11. Has co-morbidities that could affect the esophagus (eosinophilic esophagitis, esophageal varices, scleroderma, viral or fungal infection, esophageal strictures), a history of radiotherapy or cryotherapy for the esophagus; those with corrosive or physiochemical injury (with the possible inclusion in the study of those with Schatzki's ring or Barrett's esophagus).
  12. Has a history of surgical procedures that may affect the esophagus (eg, fundoplication and mechanical dilatation for esophageal strictures excluding Schatzki's ring) or a history of gastric or duodenal surgery excluding endoscopic removal of benign polyps.
  13. Developed acute upper gastrointestinal bleeding, gastric ulcer (a mucosal defect with white coating) or duodenal ulcer (a mucosal defect with white coating), within 30 days before the start of the Screening Phase (Visit 1) (with the possible inclusion of those with gastric or duodenal erosion). Participants requiring non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin treatment along with the concomitant PPI therapy to prevent gastrointestinal (GI) bleeding should not be enrolled.
  14. Has Zollinger-Ellison syndrome or gastric acid hypersecretion or a history of gastric acid hypersecretion.
  15. Is scheduled for surgery that requires hospitalization or requires surgical treatment during his/her participation in the study.
  16. Has a history of or was treated for malignancy within 5 years before the start of the Screening Phase (visit 1) (the participant may be included in the study if he/she has cured cutaneous basal cell carcinoma or cervical carcinoma in situ).
  17. Has acquired immunodeficiency syndrome (AIDS) or hepatitis, including hepatitis virus carriers ( surface antigen [HBsAg] or virus (HCV)-antibody-positive) (the participant may be included in the study if he/she is HCV-antigen or HCV-ribonucleic acid [RNA]-negative).
  18. Laboratory tests performed on visit 1 revealed any of the following abnormalities in the participant:

    1. Creatinine levels: >2 mg/dL (>177 μmol/L).
    2. (ALT) or aspartate aminotransferase (AST), or total levels: > (ULN).
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
703 participants (actual)

Study arms

  • Experimental
    Vonoprazan 10 mg

    Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE. Vonoprazan 10 mg, tablets, orally, once, daily, and Vonoprazan 20 mg, placebo-matching tablets, orally, once, daily, and Lansoprazole 15 mg placebo-matching, capsules, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing.

    Drug: Vonoprazan · Drug: Lansoprazole · Drug: Vonoprazan Placebo · Drug: Lansoprazole Placebo

  • Experimental
    Vonoprazan 20 mg

    Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE. Vonoprazan 20 mg, tablets, orally, once, daily, and Vonoprazan 10 mg, placebo-matching tablets, orally, once, daily, and Lansoprazole 15 mg, placebo-matching capsules, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing

    Drug: Vonoprazan · Drug: Lansoprazole · Drug: Vonoprazan Placebo · Drug: Lansoprazole Placebo

  • Active comparator
    Lansoprazole 15 mg

    Lansoprazole 30 mg, capsules or tablets, orally, once, daily, for up to 4 or 8 weeks or until confirmed healing of erosive esophagitis (EE) in healing phase for participants with ongoing EE. Lansoprazole 15 mg, capsules, orally, once, daily, and Vonoprazan 10 mg, placebo-matching tablets, orally, once, daily, and Vonoprazan 20 mg, placebo-matching tablets, orally, once, daily, for up to 24 weeks in maintenance phase for participants with confirmed EE healing.

    Drug: Lansoprazole · Drug: Vonoprazan Placebo

Interventions

  • Vonoprazan tablets

    Also known as: TAK-438

  • Lansoprazole capsules or tablets

    Also known as: Prevacid

  • DrugVonoprazan Placebo

    Vonoprazan placebo-matching tablets

  • DrugLansoprazole Placebo

    Lansoprazole placebo-matching capsules

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Recurrence of Erosive Esophagitis as Confirmed on Endoscopy After the 24-week Maintenance Phase

    Erosive esophagitis recurrence is defined as participants endoscopically confirmed to have erosive esophagitis (Los Angeles \[LA\] classification grades A to D) during the Maintenance Phase (24 weeks). Grade A: \>/=1 mucosal breaks \</=5 mm, none of which extends between the tops of the mucosal folds; Grade B: \>/=1 mucosal breaks \>5 mm, none of which extends between the tops of two mucosal folds; Grade C: mucosal breaks that extend between the tops of two or more mucosal folds, but which involve \<75% of esophageal circumference; Grade D: mucosal breaks which involve \>/=75% of esophageal circumference.

    Time frame: 24 weeks

Secondary outcomes

  1. Percentage of Participants With Recurrence of Erosive Esophagitis After 12 Weeks of Treatment in the Maintenance Phase

    Erosive esophagitis recurrence is defined as endoscopically confirmed to have erosive esophagitis (LA classification grades A to D) during the Maintenance Phase (12 weeks). Grade A: \>/=1 mucosal breaks \</=5 mm, none of which extends between the tops of the mucosal folds; Grade B: \>/=1 mucosal breaks \>5 mm, none of which extends between the tops of two mucosal folds; Grade C: mucosal breaks that extend between the tops of two or more mucosal folds, but which involve \<75% of esophageal circumference; Grade D: mucosal breaks which involve \>/=75% of esophageal circumference.

    Time frame: 12 weeks

  2. Number of Participants With Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug.

    Time frame: From Day 1 to 14 days after the last dose of study medication (up to 26 weeks)

  3. Number of Participants With Abnormal Clinical Laboratory Findings

    Clinical laboratory safety tests included chemistry, hematology and urinalysis. Number of participants with any markedly abnormal values in laboratory tests collected throughout study is reported. ALT = alanine aminotransferase, AST = aspartate aminotransferase, GGT = gamma-glutamyl transferase, CPK = creatine phosphokinase, BUN = blood urea nitrogen, LLN = lower limit of normal or lower reference limit, ULN = upper limit of normal or upper reference limit, g/L = grams per liter, U/L = units per liter, mmol/L = millimoles per liter, pmol/L = picomoles per liter.

    Time frame: From Day 1 to 14 days after the last dose of study medication (up to 26 weeks)

  4. Number of Participants With Abnormal Electrocardiogram (ECG) Findings

    Number of participants with any markedly abnormal 12-lead ECG findings is reported. bpm = beats per minute, msec = milliseconds, CHG= change from baseline.

    Time frame: From Day 1 to 14 days after the last dose of study medication (up to 26 weeks)

  5. Number of Participants With Abnormal Vital Sign Measurements

    The percentage of participants with any markedly abnormal vital sign measurements including (body temperature, blood pressure and pulse), mmHg = millimeters of mercury.

    Time frame: From Day 1 to 14 days after the last dose of study medication (up to 26 weeks)

  6. Change From Baseline in Serum Gastrin

    Time frame: Baseline and Weeks 4, 12 and 24

  7. Change From Baseline in Serum Pepsinogen I

    Time frame: Baseline and Weeks 4, 12 and 24

  8. Change From Baseline in Serum Pepsinogen II

    Time frame: Baseline and Weeks 4, 12 and 24

07

Results

Posted Feb 21, 2020

Participant flow

Participants took part in the study at 64 investigative sites in China, Malaysia, South Korea, and Taiwan from 01 April 2015 to 31 December 2018.

Participant flow — Overall Study
MilestoneVonoprazan 10 mgVonoprazan 20 mgLansoprazole 15 mg
Started235226242
Completed181166180
Not completed546062
Withdrew: Pretreatment event/adverse event131112
Withdrew: Major protocol deviation182522
Withdrew: Lost to follow-up514
Withdrew: Voluntary withdrawal101817
Withdrew: Lack of efficacy303
Withdrew: Reason not specified554

Outcome measures

PrimaryPercentage of Participants With Recurrence of Erosive Esophagitis as Confirmed on Endoscopy After the 24-week Maintenance Phase

Erosive esophagitis recurrence is defined as participants endoscopically confirmed to have erosive esophagitis (Los Angeles \[LA\] classification grades A to D) during the Maintenance Phase (24 weeks). Grade A: \>/=1 mucosal breaks \</=5 mm, none of which extends between the tops of the mucosal folds; Grade B: \>/=1 mucosal breaks \>5 mm, none of which extends between the tops of two mucosal folds; Grade C: mucosal breaks that extend between the tops of two or more mucosal folds, but which involve \<75% of esophageal circumference; Grade D: mucosal breaks which involve \>/=75% of esophageal circumference.

Time frame:
24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Recurrence of Erosive Esophagitis as Confirmed on Endoscopy After the 24-week Maintenance Phase
percentage of participantsVonoprazan 10 mgVonoprazan 20 mgLansoprazole 15 mg
Percentage of Participants With Recurrence of Erosive Esophagitis as Confirmed on Endoscopy After the 24-week Maintenance Phase13.3 (8.684 to 19.084)12.3 (7.765 to 18.158)25.5 (19.412 to 32.481)
SecondaryPercentage of Participants With Recurrence of Erosive Esophagitis After 12 Weeks of Treatment in the Maintenance Phase

Erosive esophagitis recurrence is defined as endoscopically confirmed to have erosive esophagitis (LA classification grades A to D) during the Maintenance Phase (12 weeks). Grade A: \>/=1 mucosal breaks \</=5 mm, none of which extends between the tops of the mucosal folds; Grade B: \>/=1 mucosal breaks \>5 mm, none of which extends between the tops of two mucosal folds; Grade C: mucosal breaks that extend between the tops of two or more mucosal folds, but which involve \<75% of esophageal circumference; Grade D: mucosal breaks which involve \>/=75% of esophageal circumference.

Time frame:
12 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Recurrence of Erosive Esophagitis After 12 Weeks of Treatment in the Maintenance Phase
percentage of participantsVonoprazan 10 mgVonoprazan 20 mgLansoprazole 15 mg
Percentage of Participants With Recurrence of Erosive Esophagitis After 12 Weeks of Treatment in the Maintenance Phase27.8 (9.695 to 53.480)10.0 (1.235 to 31.698)35.0 (15.391 to 59.219)
SecondaryNumber of Participants With Adverse Events (AEs)

An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug whether or not it is considered related to the drug.

Time frame:
From Day 1 to 14 days after the last dose of study medication (up to 26 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsVonoprazan 10 mgVonoprazan 20 mgLansoprazole 15 mg
Number of Participants With Adverse Events (AEs)157156158
SecondaryNumber of Participants With Abnormal Clinical Laboratory Findings

Clinical laboratory safety tests included chemistry, hematology and urinalysis. Number of participants with any markedly abnormal values in laboratory tests collected throughout study is reported. ALT = alanine aminotransferase, AST = aspartate aminotransferase, GGT = gamma-glutamyl transferase, CPK = creatine phosphokinase, BUN = blood urea nitrogen, LLN = lower limit of normal or lower reference limit, ULN = upper limit of normal or upper reference limit, g/L = grams per liter, U/L = units per liter, mmol/L = millimoles per liter, pmol/L = picomoles per liter.

Time frame:
From Day 1 to 14 days after the last dose of study medication (up to 26 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Clinical Laboratory Findings
ParticipantsVonoprazan 10 mgVonoprazan 20 mgLansoprazole 15 mg
Hematology: Red Blood Cells (>1.2xULN)101
Hematology: White Blood Cells (>1.5xULN)001
Hematology: Hemoglobin (<0.8xLLN)111
Hematology: Hematocrit (<0.8xLLN)011
Hematology: Platelets (<75x10^9/L)010
Hematology: Neutrophils (<0.5xLLN)100
Hematology: Eosinophils (>2xULN)220
Hematology: Lymphocytes (>1.5xULN)100
Serum Chemistry: ALT (>3xULN)110
Serum Chemistry: AST (>3xULN)202
Serum Chemistry: GGT (>3xULN)427
Serum Chemistry: CK (CPK) (>5xULN)423
Serum Chemistry: Albumin (<25 g/L)001
Serum Chemistry: Creatinine (>177 umol/L)001
Serum Chemistry: BUN (>10.7 mmol/L)242
Serum Chemistry: Uric Acid (>0.773 mmol/L)010
Serum Chemistry: Total Cholesterol (>7.72 mmol/L)253
Serum Chemistry: Triglycerides (>2.5xULN)256
Serum Chemistry: Glucose (<2.8 mmol/L)101
Serum Chemistry: Glucose (>19.4 mmol/L)100
Serum Chemistry: Potassium (<3.0 mmol/L)001
Serum Chemistry: Sodium (>150 mmol/L)100
Serum Chemistry: Vitamin B12 (<92 pmol/L)103
SecondaryNumber of Participants With Abnormal Electrocardiogram (ECG) Findings

Number of participants with any markedly abnormal 12-lead ECG findings is reported. bpm = beats per minute, msec = milliseconds, CHG= change from baseline.

Time frame:
From Day 1 to 14 days after the last dose of study medication (up to 26 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Electrocardiogram (ECG) Findings
ParticipantsVonoprazan 10 mgVonoprazan 20 mgLansoprazole 15 mg
Heart Rate (<50 bpm)874
Heart Rate (>120 bpm)010
QT Interval (>=460 msec)958
QTcF Interval (>= 500, or >= 450 with CHG >= 30)836
SecondaryNumber of Participants With Abnormal Vital Sign Measurements

The percentage of participants with any markedly abnormal vital sign measurements including (body temperature, blood pressure and pulse), mmHg = millimeters of mercury.

Time frame:
From Day 1 to 14 days after the last dose of study medication (up to 26 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Vital Sign Measurements
ParticipantsVonoprazan 10 mgVonoprazan 20 mgLansoprazole 15 mg
Body Temperature (<35.6 °Celsius)6312
Body Temperature (>37.7 °Celsius)010
Systolic Blood Pressure (<85 mmHg)200
Diastolic Blood Pressure (<50 mmHg)021
Diastolic Blood Pressure (>110 mmHg)100
Pulse (<50 bpm)143
Pulse (>120 bpm)110
SecondaryChange From Baseline in Serum Gastrin
Time frame:
Baseline and Weeks 4, 12 and 24
Reported as:
Mean · pmol/L
Change From Baseline in Serum Gastrin
pmol/LVonoprazan 10 mgVonoprazan 20 mgLansoprazole 15 mg
Baseline20.42 ± 33.96917.97 ± 21.45821.94 ± 27.905
Change at Week 410.09 ± 37.74722.76 ± 36.053-11.21 ± 24.651
Change at Week 1214.45 ± 29.43931.92 ± 45.127-8.76 ± 24.578
Change at Week 2417.47 ± 39.84737.60 ± 47.172-7.41 ± 22.210
SecondaryChange From Baseline in Serum Pepsinogen I
Time frame:
Baseline and Weeks 4, 12 and 24
Reported as:
Mean · ug/L
Change From Baseline in Serum Pepsinogen I
ug/LVonoprazan 10 mgVonoprazan 20 mgLansoprazole 15 mg
Baseline287.1 ± 249.41276.3 ± 203.46303.3 ± 253.76
Change at Week 440.5 ± 266.92139.8 ± 269.08-112.3 ± 245.22
Change at Week 12-3.1 ± 267.6589.9 ± 285.05-123.5 ± 252.45
Change at Week 245.9 ± 289.9155.4 ± 279.65-103.9 ± 218.80
SecondaryChange From Baseline in Serum Pepsinogen II
Time frame:
Baseline and Weeks 4, 12 and 24
Reported as:
Mean · ug/L
Change From Baseline in Serum Pepsinogen II
ug/LVonoprazan 10 mgVonoprazan 20 mgLansoprazole 15 mg
Baseline22.9 ± 22.4222.1 ± 17.4024.6 ± 23.83
Change at Week 43.8 ± 27.3416.5 ± 25.56-10.9 ± 23.98
Change at Week 12-1.6 ± 24.029.0 ± 26.40-10.9 ± 24.41
Change at Week 24-0.6 ± 27.235.8 ± 25.59-8.7 ± 19.61

Adverse events

Collected over Up to 26 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vonoprazan 10 mg0/235 (0%)10/235 (4.3%)81/235 (34.5%)
Vonoprazan 20 mg0/226 (0%)8/226 (3.5%)79/226 (35%)
Lansoprazole 15 mg1/242 (0.4%)12/242 (5%)79/242 (32.6%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventVonoprazan 10 mgVonoprazan 20 mgLansoprazole 15 mg
Calculus uretericRenal and urinary disorders2/2350/2260/242
Hypertensive heart diseaseCardiac disorders0/2351/2260/242
Arthritis infectiveInfections and infestations0/2351/2260/242
GastroenteritisInfections and infestations0/2351/2260/242
Spinal column injuryInjury, poisoning and procedural complications0/2351/2260/242
Gouty arthritisMusculoskeletal and connective tissue disorders0/2351/2260/242
Gouty tophusMusculoskeletal and connective tissue disorders0/2351/2260/242
Gastric adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2351/2260/242
Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2351/2260/242
Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2351/2260/242
Most frequent other events
Most frequent other events
EventVonoprazan 10 mgVonoprazan 20 mgLansoprazole 15 mg
Upper respiratory tract infectionInfections and infestations30/23529/22621/242
DiarrhoeaGastrointestinal disorders15/23521/22617/242
DyspepsiaGastrointestinal disorders18/23510/22612/242
Alanine aminotransferase increasedInvestigations13/2359/22616/242
Abdominal distensionGastrointestinal disorders5/2356/22613/242
Gastric polypsGastrointestinal disorders11/23512/2268/242
NasopharyngitisInfections and infestations12/23512/22611/242

Baseline characteristics

Randomized set included all randomized participants. The number analyzed is the number of participants with data available for analysis

Age, Continuous
Age, Continuous(years)Vonoprazan 10 mgVonoprazan 20 mgLansoprazole 15 mgTotal
Mean51.7 ± 11.7952.8 ± 13.0254.0 ± 12.8052.8 ± 12.56
Sex: Female, Male
Sex: Female, Male(Participants)Vonoprazan 10 mgVonoprazan 20 mgLansoprazole 15 mgTotal
Female596164184
Male176165178519
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Vonoprazan 10 mgVonoprazan 20 mgLansoprazole 15 mgTotal
American Indian or Alaska Native0000
Asian235225242702
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0101
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)Vonoprazan 10 mgVonoprazan 20 mgLansoprazole 15 mgTotal
China163159169491
Malaysia24242472
Korea, Republic Of26232776
Taiwan, Province Of China22202264
Height
Height(centimeter (cm))Vonoprazan 10 mgVonoprazan 20 mgLansoprazole 15 mgTotal
Mean166.7 ± 8.35166.1 ± 8.31167.1 ± 8.01166.7 ± 8.22
Weight
Weight(kilogram (kg))Vonoprazan 10 mgVonoprazan 20 mgLansoprazole 15 mgTotal
Mean70.03 ± 12.13768.10 ± 11.31469.19 ± 11.07569.12 ± 11.528
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Vonoprazan 10 mgVonoprazan 20 mgLansoprazole 15 mgTotal
Mean25.10 ± 3.44924.58 ± 3.05224.77 ± 3.47524.82 ± 3.338
Smoking Classification
Smoking Classification(Participants)Vonoprazan 10 mgVonoprazan 20 mgLansoprazole 15 mgTotal
The Participant Has Never Smoked157135147439
The Participant Is a Current Smoker504755152
The Participant Is an Ex-smoker284440112

8 further baseline measures are reported on the registry.

08

Study locations

72 sites
  • Beijing Chao Yang Hospital
    Beijing, Beijing 100020, China
  • Peking Union Medical College Hospital
    Beijing, Beijing 100032, China
  • Peking University First Hospital
    Beijing, Beijing 100034, China
  • The General Hospital of Peoples Armed Police Forces China
    Beijing, Beijing 100039, China
  • Beijing Tongren Hospital, Capital Medical Univeristy
    Beijing, Beijing 100370, China
  • Fuzhou General Hospital of Nanjing Military Command
    Fuzhou, Fujian 350100, China
  • Guangdong General Hospital
    Guangzhou, Guangdong 510080, China
  • The Sixth Affiliated Hospital of Sun Yat- Sen University
    Guangzhou, Guangdong 510655, China
  • Peking University Shenzhen Hospital
    Shenzhen, Guangdong 518000, China
  • Union Hospital of Tongji Medical College of Huazhong Science and Techology University
    Wuhan, Hubei 430022, China
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science & Techology
    Wuhan, Hubei 430030, China
  • Peoples Hospital of Wuhan University
    Wuhan, Hubei 430060, China
  • The 2nd Xiangya Hospital Central South University
    Changsha, Hunan 410011, China
  • Chenzhou No.1 People's Hospital
    Chenzhou, Hunan 432000, China
  • Xiangtan Central Hospital
    Xiangtan, Hunan 411100, China
  • The First People's Hospital of Changzhou
    Changzhou City, Jiangsu 213003, China
  • Jiangsu Province People's Hospital
    Nanjing, Jiangsu 210029, China
  • Yangzhou 1st Hospital
    Yangzhou, Jiangsu 225001, China
  • No.2 Hospital Affiliated to Jilin University
    Changchun, Jilin 130041, China
  • China-Japan Union Hospital of Jilin University
    Jilin, Jilin 130033, China
  • Jilin central Hospital
    Jilin, Jilin 132011, China
  • Jilin Siping Central Hospital
    Siping, Jilin 136000, China
  • General Hospital of Ningxia Medical University
    Yinchuan, Ningxia 750004, China
  • Ruijin Hospital, Shanghai Jiaotong Uni. School of Med.
    Shanghai, Shanghai 200025, China
  • Zhongshan Hospital Fudan University
    Shanghai, Shanghai 200032, China
  • TongJi Hospital of Tongji University
    Shanghai, Shanghai 200065, China
  • Sixth Peoples Hospital of Shanghai
    Shanghai, Shanghai 200233, China
  • Tianjin Medical University General Hospital
    Tianjing, Tianjin 300052, China
  • The 2nd Hospital of Tianjin Medical University
    Tianjin, Tianjin 300211, China
  • The First Affiated Hospital of Kunming Medical College
    Kunming, Yunnan 650032, China
  • 2nd Affiliated Hospital, Zhejiang Univ. School of Medicine
    Hangzhou, Zhejiang 310009, China
  • Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
    Hangzhou, Zhejiang 310016, China
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, 100050, China
  • PLA.The Military General Hospital of Beijing
    Beijing, 100853, China
  • Beijing, China
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, 0, China
  • The First Affiliated Hospital, Sun Yat-sen University
    Guangzhou, 510080, China
  • 1st Affiliated Hospital of Zhejiang University
    Hangzhou, China
  • The First Affiliated Hospital of NanChang University
    Nanchang, China
  • The Affiliated DrumTower Hospital of Nanjing University
    Nanjing, 210008, China
  • Tianjing, China
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, Korea, Republic of
  • Seoul National University Hospital
    Seoul, Gyeonggi-do 03080, Korea, Republic of
  • Kyungpook National University Medical Center
    Daegu, Gyeongsangbuk-do 41404, Korea, Republic of
  • Wonkwang University School Of Medicine & Hospital
    Iksan-si, Jeollabuk-do 54538, Korea, Republic of
  • Pusan National University Hospital
    Busan, 49241, Korea, Republic of
  • Yeungnam University Hospital
    Daegu, 42415, Korea, Republic of
  • Kyung Hee University Hospital
    Seoul, 02447, Korea, Republic of
  • Korea University Anam Hospital
    Seoul, 02841, Korea, Republic of
  • Kangbuk Samsung Hospital
    Seoul, 03181, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • The Catholic University of Korea, Seoul St. Marys Hospital
    Seoul, 06591, Korea, Republic of
  • Hospital Sultana Bahiyah
    Alor Setar, Kedah 5460, Malaysia
  • Hospital Raja Perempuan Zainab II
    Kota Bahru, Kelantan 15586, Malaysia
  • Hospital Tengku Ampuan Afzan
    Kuantan, Pahang 25100, Malaysia
  • Hospital Queen Elizabeth
    Kota Kinabalu, Sabah 88586, Malaysia
  • Hospital Ampang
    Ampang, Selangor 68000, Malaysia
  • Hospital Universiti Sains Malaysia
    Kelantan, 16150, Malaysia
  • Hospital Kuala Lumpur
    Kuala Lumpur, 50586, Malaysia
  • University Malaya Medical Centre
    Kuala Lumpur, 59100, Malaysia
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
    Kaohsiung, 807, Taiwan
  • E-Da Hospital
    Kaohsiung, 824, Taiwan
  • Kaohsiung Chang Gung Memorial Hospital
    Kaohsiung, 833, Taiwan
  • China Medical University Hospital
    Taichung, 333, Taiwan
  • Chung Shan Medical University Hospital
    Taichung, 402, Taiwan
  • National Cheng Kung University Hospital
    Tainan, 704, Taiwan
  • Taipei Medical University Hospital
    Taipei City, 110, Taiwan
  • National Taiwan University Hospital
    Taipei, 100, Taiwan
  • Taipei Veterans General Hospital
    Taipei, 112, Taiwan
  • Tri-Service General Hospital
    Taipei, 144, Taiwan
  • Chang Gung Memorial Hospital, Linkou
    Taoyuan County, 333, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2015 to primary completion in Dec 2018, 44 months.

Results were first posted in Feb 2020, 1 year 1 month after primary completion.

Of 18 phase 3 interventional studies under Esophagitis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 34. This study's 44 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2015
First posted
Mar 17, 2015
StartActual
Apr 1, 2015
Primary completionActual
Dec 24, 2018
CompletionActual
Dec 31, 2018
Results first posted
Feb 21, 2020
Last update
Feb 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02388737
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Mar 17, 2015
Start date
Apr 1, 2015
Primary completion
Dec 24, 2018
Completion
Dec 31, 2018
Results posted
Feb 21, 2020
Last update
Feb 21, 2020

Study contacts

Medical Director Clinical Science, MD
study director · Takeda Development Center Asia, Pte Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vonoprazan

Start the discussion